Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting

Group 1 - Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of atopic dermatitis [AD] [2] - The study is still in early stages, indicating potential for future developments in the treatment of AD [2] - The article highlights the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and a model portfolio of small and mid-cap stocks [2] Group 2 - The author of the article is Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace [1] - The service offers a two-week free trial and a subscription model priced at $49 per month or$399 per year with a discount for annual sign-ups [1] - The article does not contain any stock positions or plans to initiate positions in the companies mentioned [3]